References
1. Neonatal-perinatal database and birth defects surveillance. Report of the regional review meeting. URL: http://apps.who.int/iris/handle/10665/204361 . (date of access 15.05.2016)
2. Connor M., Ferguson-Smith M. Essential Medical Genetics. 5th ed. Oxford: Blackwell Scientific Publications, 1997.
3. Emeliyanenko E.S., Isayev A.A., Pismennaya E.E., Levitskaya N.A., Kostin I.N. Innovative technologies in prenatal diagnosis: doctor and patient opinions. Doctor.Ru. 2017; 9(138): 38-43.2017; 9: 38-43. (in Russian)
4. URL: http://www.eurocat-network.eu/ACCESSPREVALENCEDATA/Pre-valenceTables .
5. URL: http://www.eurocat-network.eu/prenatalscreeninganddiag-nosis/prenataldetection(pd)rates .
6. Syngelaki A., Chelemen T., Dagklis T., et al. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenat Diagn. 2011; 31 (1): 90-102. PMID: 21210483.
7. Salomon L.J., Alfirevic Z., Bilardo C.M., Chalouhi G.E., Ghi T., Kagan K.O., Lau T.K., Papageorghiou A.T., Raine-Fenning N.J., Stirnemann J., Suresh S., Tabor A, Timor-Tritsch I.E., Toi A., Yeo G. ISUOG Practice Guidelines: performance of firsttrimester fetal ultrasound scan. Ultrasound Obstet Gynecol. 2013; 41: 102-13.
8. On approval of the procedure for providing medical care in the profile of "obstetrics and gynecology (with the exception of the use of assisted reproductive technologies)": Order of the Ministry of Healthcare of Russia of 12.11.2012 No. 572n. (in Russian)
9. Miltoft C.B., Rode L., Ekelund C.K., Sundberg K., et al. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting. Ultrasound Obstet. Gynecol. 2018; 51: 470-9.
10. Kenkhuis M.J.A., Bakker M., Bardi F., Fontanella F., et al. Effectiveness of 12-13-week scan for early diagnosis of fetal congenital anomalies in the cell-free DNA era. Ultrasound Obstet. Gynecol. 2018; Vol. 51: 463-9.
11. Pregnancy early terms. From pregravid preparation for healthy gestation. 3rd ed., Revised and enlarged. Edited by V.E. Radzinsky, A.A. Orazmuradova. Mosraw: StatusPraesens, 2018. 800 p. (in Russian)
12. Grande M., Jansen F.A., Blumenfeld Y.J., Fisher A., et al. Genomic microarray in fetuses with increased nuchal translucency and normal karyotype: a systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2015; 46: 650-8.
13. Pereira S., Ganapathy R., Syngelaki A., Maiz N., et al. Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects. Ultrasound Obstet Gynecol. 2011; 117: 1384-91.
14. Chelemen T., Syngelaki A., Maiz N., Allan L., et al. Contribution of ductus venosus Doppler in first-trimester screening for major cardiac defects. Fetal Diagn Ther. 2011; 29: 127-34.
15. Cuckle H., Benn P., Wright D. Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatol. 2005; 29: 252-7.
16. Kagan K.O., Wright D., Spencer K., Molina F.S., et al. First trimester screening for trisomy 21 by free beta-human chorionic gonadotropinand pregnancy-associated plasma protein-A: impact of maternal andpregnancy characteristics. Ultrasound Obstet Gynecol. 2008; 31: 493-502.
17. Nicolaides K.H. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011; 31 (1): 7-15.
18. Emeliaynenko E.S., Vetrova N.V., Masyuk S.V., Isaev A.A., Evtushenko I.D. Prenatal diagnosis of chromosomal abnormalities: clinical- and cost-effectiveness. Doctor.Ru. 2016; 3 (120): 43-51. (in Russian)
19. Gil M.M., Akolekar R., Quezada M.S., Bregant B., et al. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: meta-analysis. Fetal Diagn Ther. 2014; 35 (3): 156-73.
20. Gil M.M., Quezada M.S., Revello R., Akolekar R., et al. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2015; 45 (3): 249-66.
21. Gil M.M., Revello R., Poon L.C., Akolekar R., et al. Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test. Ultrasound Obstet Gynecol. 2016; 47 (1): 45-52.
22. Borrell A. A new comprehensive paradigm for prenatal diagnosis: seeing the forest through the trees. Ultrasound Obstet Gynecol. 2008; 52: 563-8.
23. Taylor-Phillips S., Freeman K., Geppert J., Agbebiyi A., et al. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and metaanalysis. BMJ Open. 2016; 6. Article ID e010002.
24. Kagan K.O., Sroka F., Sonek J., Abele H., et al. First-trimester risk assessment based on ultrasound and cell-free DNA vs combined screening: a randomized controlled trial. Ultrasound Obstet Gynecol. 2018; 51: 437-44.
25. Ghi T., Sotiriadis A., Calda P., Da Silva Costa F., et al.; on behalf of the International Society of Ultrasound in Obstetrics and Gynecology. ISUOG Practice Guidelines: invasive procedures for prenatal diagnosis in obstetrics. Ultrasound Obstet. Gynecol. 2016; 48: 256-68.
26. Petrovski S., Aggarval W., Jordano J.L., Stosic M., et al. Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study. Lancet. 2019; 393: 758-67.
27. Pismennaya E.E., Korablin Yu.A., Emelyanenko E.S., Isaev A.A. Prenatal diagnosis: a sociological analysis The Humanities. 2017; 1: 35-46. (in Russian)
29. Smirnova A.Yu., Khamoshina M.B., Zayakina L.B. Risk factors of the birth of the child with congenital anomalies in Primorsky Region. Vestnik RUDN [Bulletin of Russian Peoples' Friendship University] 2009; 5: 54-63. (in Russian)
29. Decree of the President of the Russian Federation “On Approval of the Concept of the Demographic Policy of the Russian Federation for the Period up to 2025” dated 09.10.2007 No. 1351. URL: http://base.garant.ru/191961/ (circulation date 16.08.2017). (in Russian)